Epidemiology of infections after solid-organ transplantation

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 1, 2001, Pages

  Snydman, D R ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL INFECTION; CANDIDIASIS; CONFERENCE PAPER; DISEASE COURSE; GRAFT INFECTION; GRAFT REJECTION; IMMUNE DEFICIENCY; INCIDENCE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

CROSS INFECTION; HUMANS; INCIDENCE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 0034984568     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320897     Document Type: Conference Paper

References (40)

1. Infections in solid organ transplantation recipients
2. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients
3. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients
4. Hepatitis C virus and organ transplantation
5. Infectious disease complications of renal transplantation
6. Infections with cytomegalovirus and other herpesvirus in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies
7. Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation
8. Infection in organ transplant recipients
9. Infection in the renal transplant recipient
10. Infections in liver transplant recipients
11. Infectious complications after cardiac transplantation in man
12. Infection after lung transplantation
13. A randomized, placebo controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal transplants
14. Infections after liver transplantation: An analysis of 101 consecutive cases
15. Listeriosis in renal transplant recipients: Report of an outbreak and review of 102 cases
16. Histoplasmosis in renal allograft recipients: Two large urban outbreaks
17. Coccidioidomycosis in renal replacement therapy
18. Influence of rejection therapy on fungal and nocardial infections in renal-transplantation recipients
19. Primary cytomegalovirus and opportunistic infections: Incidence in renal transplant recipients
20. Cytomegalovirus as a risk factor in renal transplantation
21. Human herpesvirus-6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant patients at risk for primary cytomegalovirus infection
22. Human herpesvirus-6 infection after liver transplantation
23. Human herpes virus-6 in transplantation: An emerging pathogen
24. Adenovirus infection in adult orthotopic liver transplant recipients: Incidence and clinical significance
25. Adenovirus infection in pediatric liver transplant recipients
26. Varicella in children with renal transplants
27. Progressive multifocal leukoencephalopathy in renal transplant recipients
28. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder
29. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation
30. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation
31. Efficacy of pyramethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients
32. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients
33. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: Clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis
34. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole
35. High dose acyclovir compared with short course pre-emptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients
36. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial
37. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors
38. Cytomegalovirus immune globulin prophylaxis in liver transplantation: A randomized, double-blind, placebo controlled trial
39. Randomized comparison of ganciclovir high dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients
40. A prospective comparison of molecular diagnostic techniques for early detection of cytomegalovirus in liver transplant recipients